The antiserum was produced against synthesized peptide derived from human c-Jun around the phosphorylation site of Tyr170. AA range:137-186

Phospho-AP-1 (Y170) Polyclonal Antibody detects endogenous levels of AP-1 protein only when phosphorylated at Y170.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):PVyAN

JUN

Transcription factor AP-1;jun;c-jun；AP-1

JUN ;
Transcription factor AP-1 ;
Activator protein 1 ;
AP1 ;
Proto-oncogene c-Jun ;
V-jun avian sarcoma virus 17 oncogene homolog ;
p39

This gene is the putative transforming gene of avian sarcoma virus 17. It encodes a protein which is highly similar to the viral protein, and which interacts directly with specific target DNA sequences to regulate gene expression. This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies. [provided by RefSeq, Jul 2008],

Function:Transcription factor that recognizes and binds to the enhancer heptamer motif 5'-TGA[CG]TCA-3'.,PTM:Phosphorylation enhances the transcriptional activity. Phosphorylated by PRKDC.,similarity:Belongs to the bZIP family.,similarity:Belongs to the bZIP family. Jun subfamily.,similarity:Contains 1 bZIP domain.,subunit:Heterodimer with either FOS or BATF3. Interacts with HIVEP3 (By similarity). Interacts with SMAD3/SMAD4 heterodimers. Interacts with MYBBP1A, SPIB and TCF20. Interacts with COPS5; indirectly leading to its phosphorylation. Interacts with DSIPI; this interaction inhibits the binding of active AP1 to its target DNA.,

Nucleus.

Expressed in the developing and adult prostate and prostate cancer cells.

>>Endocrine resistance ;
>>MAPK signaling pathway ;
>>ErbB signaling pathway ;
>>cAMP signaling pathway ;
>>Mitophagy - animal ;
>>Apoptosis ;
>>Wnt signaling pathway ;
>>Osteoclast differentiation ;
>>Focal adhesion ;
>>Tight junction ;
>>Toll-like receptor signaling pathway ;
>>NOD-like receptor signaling pathway ;
>>C-type lectin receptor signaling pathway ;
>>IL-17 signaling pathway ;
>>Th1 and Th2 cell differentiation ;
>>Th17 cell differentiation ;
>>T cell receptor signaling pathway ;
>>B cell receptor signaling pathway ;
>>TNF signaling pathway ;
>>Neurotrophin signaling pathway ;
>>GnRH signaling pathway ;
>>Estrogen signaling pathway ;
>>Oxytocin signaling pathway ;
>>Relaxin signaling pathway ;
>>Non-alcoholic fatty liver disease ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Cocaine addiction ;
>>Amphetamine addiction ;
>>Epithelial cell signaling in Helicobacter pylori infection ;
>>Pathogenic Escherichia coli infection ;
>>Shigellosis ;
>>Salmonella infection ;
>>Pertussis ;
>>Yersinia infection ;
>>Leishmaniasis ;
>>Chagas disease ;
>>Hepatitis B ;
>>Measles ;
>>Human T-cell leukemia virus 1 infection ;
>>Kaposi sarcoma-associated herpesvirus infection ;
>>Epstein-Barr virus infection ;
>>Human immunodeficiency virus 1 infection ;
>>Coronavirus disease - COVID-19 ;
>>Pathways in cancer ;
>>Viral carcinogenesis ;
>>Chemical carcinogenesis - receptor activation ;
>>Chemical carcinogenesis - reactive oxygen species ;
>>Colorectal cancer ;
>>Renal cell carcinoma ;
>>Breast cancer ;
>>Choline metabolism in cancer ;
>>PD-L1 expression and PD-1 checkpoint pathway in cancer ;
>>Inflammatory bowel disease ;
>>Rheumatoid arthritis ;
>>Lipid and atherosclerosis ;
>>Fluid shear stress and atherosclerosis